Senores Pharmaceuticals Ltd

Stage 3 · Topping · week 1

As of 16 Oct 2026, Senores Pharmaceuticals is in Stage 3 — topping, where an uptrend loses steam, in its first week (since 12 Oct 2026). It closed at ₹1,318, 15.0% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.6% of stocks are in Stage 2.

Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. More about the company

₹1,318.4
+4.73% today
₹6,072 Cr · Mid cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is SENORES early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-15.0%
₹710.3 lo₹1,550.9 hi
15.0% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 1
1w13w26w
Week 1 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
20.3%
200 DMA: ₹1,096.3 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
1.21x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -4.4% vs MA50 -1.0%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-4.2%
3M
-6.2%
6M
+48.1%
YTD
+60.6%
1Y
+84.4%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2024-12-30 → 2026-10-16
S? 41w
S2 21w
S2 24w
2024-12-302026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S2 21w → S3 6w → S2 24w → S3 1w current
Total tracked: 93 weeks across 5 stage runs.
Scan Membership
Prop Scan
Latest: 2026-09-11
Pullback Hunter
Latest: 2026-08-21
60 appearances in last 60 days. First seen: 2026-07-17.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S3
Wk 1 · Vol 1.21x
2026-10-15S3
Wk 1 · Vol 0.67x
2026-10-14S3
Wk 1 · Vol 0.61x
2026-10-13S3
Wk 1 · Vol 0.71x
2026-10-12S32→3
Wk 1 · Vol 0.55x
2026-10-09S2
Wk 24 · Vol 0.59x
2026-10-08S2
Wk 24 · Vol 1.17x
2026-10-07S2
Wk 24 · Vol 0.75x
2026-10-06S2
Wk 24 · Vol 1.20x
2026-10-05S2
Wk 24 · Vol 1.06x
2026-10-01S2
Wk 23 · Vol 1.41x
2026-09-30S2
Wk 23 · Vol 1.05x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹1,419
200 DMA
₹1,096.3
52W High
₹1,550.9
52W Low
₹710.3
5D Low
₹1,258.8
Resistance levels (recent highs)
20d High
₹1,403.7
60d High
₹1,550.9
120d High
₹1,550.9
250d High
₹1,550.9
Next resistance
+6.5%
to 20d High
Ask the Market AI about SENORESAsk →
P/E (TTM)
42.3
Forward 25.8
Earnings Growth (YoY)
+108.9%
Revenue +53.4%
ROE
+13.8%
Profit margin +18.4%
About this companyHealth Care· Pharmaceuticals

Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.